Mobile version of Hanspub

文章引用说明 更多>> (返回到该文章)

Bingle, L., Singleton, V. and Bingle, C.D. (2002) The Putative Ovarian Tumour Marker Gene HE4 (WFDC2), Is Expressed in Normal Tissues and Undergoes Complex Alternative Splicing to Yield Multiple Protein Isoforms. Oncogene, 21, 2768-2773.
http://dx.doi.org/10.1038/sj.onc.1205363

被以下文章引用:

  • 标题: 人附睾蛋白4临床应用研究进展Advances of Human Epididymis Protein 4 in Clinical Application

    作者: 王雅菲, 托娅, 王丽娟

    关键字: HE4, 卵巢癌, 肺癌, 恶性胸腔积液HE4, Ovarian Cancer, Lung Cancer, Malignant Pleural Effusion

    期刊名称: 《Asian Case Reports in Oncology》, Vol.5 No.3, 2016-07-29

    摘要: 人附睾蛋白4 (human epididymis 4, HE4)是近年来新发现的肿瘤标志物,血清HE4水平作为卵巢癌诊断、疗效评估及预后判断的新指标已经逐渐应用于临床。现有研究显示HE4在肺癌患者血清和恶性胸腔积液患者胸水中呈现较高水平表达,提示其在肺癌诊断、预后评估方面的良好作用。本文就HE4在卵巢癌及肺癌的临床应用作一综述。 Human epididymis protein 4 (HE4) as a novel tumor marker is found in recent years. Serum HE4 level as a new indicator for the diagnosis, therapeutic evaluation and prognosis of ovarian cancer has been applied to the clinical gradually. The existing research shows serum HE4 of patients with lung cancer and HE4 in pleural effusion of patients with malignant pleural effusion presented higher levels of expression, suggesting a good role in the diagnosis and the prognosis evaluation of lung cancer. This article reviews the research of HE4 in clinical application of ovarian cancer and lung cancer.